ICML 2017 | CLL update from ICML17: Current treatment and future directions for patients
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Barbara Eichhorst, MD, of the University Hospital Cologne, Germany, gives an overview of the different treatment options for patients with relapsed/refractory CLL, with respect to the time of relapse. She explains that if patients have a late relapse, in the absence of TP53 mutation, guidelines still recommend chemo-immunotherapy. Patients who have an earlier relapse, should receive a novel agent such as the BTK inhibitor ibrutinib and the PI3 kinase inhibitor idelalisib. Although these compounds have shown great efficacy, sometimes side effects lead to patients having to stop treatment. Venetoclax has shown to be a good alternative with a good response rate. Dr Eichorst explains that the future of treatment for relapsed CLL sees the combination of these novel agents. Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland.
This video was supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. The company had no influence on the production of the content.
- future of treatment
- ICML 2017 Chronic Lymphocytic Leukemia
- kinase inhibitor
- novel agent
- novel agents
- response rate
- side effects
- stop treatment
Get great new content delivered to your inboxSign up